Le Lézard
Classified in: Science and technology
Subject: SHA

Servotronics Announces Important Development with the Annual Meeting of Shareholders


? Star Equity has withdrawn its nominees for election to the Company's Board of Directors, thus ending the proxy contest ?

? Vote now on the Company's BLUE proxy card to have your vote counted ?

ELMA, N.Y., June 5, 2023 /PRNewswire/ -- Servotronics, Inc. (NYSE American ? SVT) a designer and manufacturer of servo-control components and other advanced technology products today announced that on June 1, 2023 Star Equity Fund, L.P. notified the Company that Star Equity was withdrawing its two nominees for election to the Company's Board of Directors. The withdrawal of Star Equity's nominees is not the result of any concessions by the Company nor a negotiated settlement with Star Equity.

Due to the limited time between Star Equity's withdrawal of its nominees and the June 9, 2023 Annual Meeting, we are not able to provide shareholders a revised proxy card that does not include the withdrawn nominees.  Shareholders who wish to vote on the election of directors and other proposals to be considered at the Annual Meeting should vote on the Company's BLUE proxy card or voting instruction form.

For shareholders who have already voted on the Company's BLUE proxy card for the Company's nominees ??Brent D. Baird, Edward C. Cosgrove, William F. Farrell, Jr., Karen L. Howard, Christopher M. Marks and Evan H. Wax?? there is no need to vote again. Your previous vote will count.

Star Equity has stated that proxies previously received on the white universal proxy card will be delivered to the Company and voted as instructed unless they are revoked. However, Star Equity will not vote any further proxies received from shareholders after the date Star Equity withdrew its nominees.  Also, any votes cast for the withdrawn nominees using either the BLUE or white proxy card will be disregarded and not be counted.

All shareholders are encouraged to review the Company's proxy statement for more complete information with respect to the Annual Meeting. If you have already submitted your proxy card, you have the power to revoke it at any time before it is exercised as provided under the "Question and Answers About the Proxy Materials and the Annual Meeting" section of the proxy statement.

Shareholders who have any questions or need assistance voting may contact the Company's proxy solicitors, Georgeson, LLC, toll-free at (866) 767-8867.

ABOUT SERVOTRONICS

The Company is composed of two groups ? the Advanced Technology Group (ATG) and the Consumer Products Group (CPG). The ATG primarily designs, develops and manufactures servo controls and other components for various commercial and government applications (i.e., aircraft, jet engines, missiles, manufacturing equipment, etc.). The CPG designs and manufactures cutlery, bayonets, pocket knives, machetes and combat knives, survival, sporting, agricultural knives and other edged products for both commercial and government applications.

SERVOTRONICS, INC. (SVT) IS LISTED ON NYSE American

SOURCE Servotronics, Inc.


These press releases may also interest you

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: